Glifempa m 25/500mg 30’s tablets contain empagliflozin, an orally-active inhibitor of the sodium-glucose co-transporter 2 (SGLT2). Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible for glucose reabsorption from the glomerular filtrate back into circulation. Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2 empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion. Empiget (Empagliflozin) is an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus as: Monotherapy: When diet and exercise alone do not provide adequate glycemic control in patients for whom use of metformin is considered inappropriate due to intolerance. Add-on combination therapy: In combination with other glucose-lowering medicinal products, including insulin, diet and exercise do not provide adequate glycemic control.
Empagliflozin is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
Empagliflozin is also used to lower the risk of dying or needing to be in a hospital for heart failure when your heart cannot pump blood properly.
Empagliflozin is not for treating type 1 diabetes.